Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline in 2024, with several candidates entering late ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the respiratory community has seen a continuous growth in the number of biologics ...

Pfizer's Q4 adjusted EPS was $0.63 ... Xeljanz and Oncology biosimilars. Read Next: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts Fourth-quarter 2024 Comirnaty ...

Pfizer has beaten Wall Street's revenue estimate ... In addition, in early 2025, Teva and Amgen launched biosimilars of Stelara, whose sales account for about 12% of Johnson & Johnson's total ...

Pfizer expects to sufficiently de-lever its ... and the impact of regulatory exclusivity expiry in Canada; and Oncology biosimilars globally, down 35% operationally, driven primarily by supply ...

Pfizer PFE1.02%increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...